Pro-life CEO predicts Trump FDA nominee could bring renewed scrutiny to abortion drug risks
Trump's FDA nominee Heidi Overton could bring renewed scrutiny to mifepristone, says Americans United for Life CEO who calls her a "pro-life" pick.
Fox News
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Fox News.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Fox News (www.foxnews.com), a Tier B publisher, filed this report on . CurrentWire published this page 21 minutes later, on .
Signal breakdown
CurrentWire ranked this story 71.9 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.9 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 10 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (4), Trump FDA (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.